Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.

被引：0
|
作者：
Maruzzo, Marco
Basso, Umberto
Diminutto, Alberto
De Giorgi, Ugo
Fratino, Lucia
Lo Re, Giovanni
D'Angelo, Alessandro
Donini, Maddalena
Verderame, Francesco
Ratta, Raffaele
Procopio, Giuseppe
Campadelli, Enrico
Massari, Francesco
Gasparro, Donatello
Macrini, Sveva
Messina, Caterina
Giordano, Monica
Maines, Francesca
Zagonel, Vittorina
Caffo, Orazio
机构：
[1] IRCCS, IOV, Med Oncol 1, Padua, Italy
[2] IRCCS, Ist Oncol Veneto, Padua, Italy
[3] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Natl Canc Ctr CRO, Aviano, Italy
[5] Santa Maria Degli Angeli Gen Hosp, Pordenone, Italy
[6] Civil Hosp, Taormina, Italy
[7] Ist Ospitalieri Cremona, Cremona, Italy
[8] Cervello Hosp, Palermo, Italy
[9] Unicampus Univ, Rome, Italy
[10] Ist Nazl Tumori, Fdn IRCCS, Oncol Unit 1, I-20133 Milan, Italy
[11] Civil Hosp, Lugo Di Romagna, Italy
[12] Univ Verona, Med Oncol, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[13] Univ Hosp Parma, Parma, Italy
[14] Univ Hosp, Udine, Italy
[15] Pope John Paul XXIII Hosp, Med Oncol Unit, Bergamo, Italy
[16] Santa Anna Hosp, Como, Italy
[17] Santa Chiara Hosp, Trento, Italy
[18] IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [42] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [43] Assessment of serial serum chromogranin A (CGA) and CGA/PSA ratio and treatment response with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Lewis, Akeem Ronell
    Costello, Brian Addis
    Quevedo, Fernando
    Pagliaro, Lance C.
    Weinshilboum, Richard M.
    Wang, Leiwei
    Kalari, Krishna Rani
    Kohli, Manish
    Tan, Winston
    Giridhar, Karthik
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17036 - E17036
  • [44] Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
    Shameem, Raji
    Hamid, Muhammad Saad
    Xu, Kevin Y.
    Wu, Shenhong
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 64 - 72
  • [45] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [47] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [48] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [49] Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharide, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 428 - 432
  • [50] Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.
    Tucci, Marcello
    Vignani, Francesca
    Bertaglia, Valentina
    Buttigliero, Consuelo
    Berruti, Alfredo
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345